Diabetes mellitus (DM) is a important health problem that induces ernestful complications
and it causes significant morbidity owing to specific microvascular complications such as …

Previous research has implicated vascular endothelial growth factor (VEGF) in the
pathogenesis of diabetic retinopathy (DR). Although many studies reviewed the use of anti …

PURPOSE: To report the findings at 1 year of a study comparing repeated intravitreal
bevacizumab (ivB) and modified Early Treatment of Diabetic Retinopathy Study (ETDRS) …

Diabetic macular edema (DME), defined as a retinal thickening involving or approaching the
center of the macula, represents the most common cause of vision loss in patients affected …

Patients struggling with diabetes are at elevated risks for several sight-threatening diseases,
including proliferative diabetic retinopathy (DR). DR manifests in two stages: first, the retinal …

In the past years, the management of diabetic retinopathy (DR) relied primarily on a good
systemic control of diabetes mellitus, and as soon as the severity of the vascular lesions …

Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite
that DME represents a sight‐threatening condition, it is also among the most accessible to …

Purpose: To investigate the efficiency of intravitreal dexamethasone implant in patients with
chronic diabetic macular edema nonresponsive to three consecutive monthly intravitreal …

Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving
vascular endothelial growth factor (VEGF) and other inflammatory mediators. DME is …

Diabetic retinopathy is one of the major complications of diabetes mellitus and a leading
cause of visual loss. Diabetic macular edema (DME) is an ocular manifestation of the …